Notice of Correction to NOT-CA-23-071: Notice of Special Interest (NOSI): Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials
Notice Number:
NOT-CA-23-075

Key Dates

Release Date:

June 28, 2023

Related Announcements

  • June 22, 2023:  Notice of Special Interest (NOSI): Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical. See NOSI NOT-CA-23-071

Issued by

National Cancer Institute (NCI)

Purpose

This Notice corrects the Application Due Date(s) in NOT-CA-23-071, Notice of Special Interest (NOSI): Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials.

Currently reads:

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent:

  • PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

  • Application Due Date(s) – February 28, 2024, and June 30, 2025, by 5:00 PM local time of applicant organization for possible funding in FY2023, FY2024, and FY2025, respectively. The Expiration Date of this NOSI is July 1, 2025.
  • For funding consideration, applicants must include “NOT-CA-23-071” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Corrected to read (in bold italics):

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent:

  • PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

  • Application Due Date(s) – February 28, 2024, and June 30, 2025, by 5:00 PM local time of applicant organization for possible funding in FY2024, and FY2025, respectively. The Expiration Date of this NOSI is July 1, 2025.
  • For funding consideration, applicants must include “NOT-CA-23-071” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

All other aspects of NOT-CA-23-071 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Ellen Richmond, MS, GNP-BC
Division of Cancer Prevention
National Cancer Institute (NCI)
Telephone: 240-276-7043
E-mail: richmone@mail.nih.gov

Financial/Grants Management Contact(s)

Crystal Wolfrey 
National Cancer Institute (NCI) 
Telephone: 240-276-6277 
Email: crystal.wolfrey@mail.nih.gov